Thus, although other proteins might be affected by inhibition by 4× PLDLS, the fact that EVI1-expressing cells are more sensitive to the effect of PLDLS inhibition suggests that there is a therapeutic window for targeting this interaction in AML patients. The gene discussed is MECOM; the disease is acute myeloid leukemia.